What the FDA labels say about taking them together
Cimetidine and midazolam
Midazolam's FDA label of January 1, 2024 names cimetidine in its drug interactions section; the cimetidine label PlainMeds reads does not name midazolam. The midazolam label: “Concomitant administration with drugs that are known to inhibit the P450-3A4 enzyme system, such as cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole, may result in prolonged …”
Check it at the source: the cimetidine FDA label on DailyMed (effective July 15, 2026, Mylan Pharmaceuticals Inc.); the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC).
What does the cimetidine label say about midazolam?
Cimetidine's label (effective July 15, 2026) does not name midazolam in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cimetidine), Mylan Pharmaceuticals Inc., effective July 15, 2026 (SPL set 06c0a509-026f-44e0-9975-a94a8de51d43), via openFDA; the full label on DailyMed
What does the midazolam label say about cimetidine?
Midazolam label, drug interactionsOther Drug Interactions Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the P450-3A4 enzyme system such as cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole.
N/A label (Rafa Laboratories, Ltd., February 18, 2026), drug interactionsCytochrome P450-3A4 Inhibitors Caution is advised when Midazolam Injection is administered concomitantly with drugs that are known to inhibit the P450-3A4 enzyme system (e.g., cimetidine, erythromycin, diltiazem, verapamil, ketoconazole, and itraconazole).
Midazolam In Sodium Chloride label (WG Critical Care, LLC., July 31, 2025), drug interactionsConcomitant administration with drugs that are known to inhibit the P450-3A4 enzyme system, such as cimetidine (not ranitidine), erythromycin, diltiazem, verapamil, ketoconazole and itraconazole, may result in prolonged sedation due to a decrease in plasma clearance of midazolam.
Source: FDA drug label (N/A, NDA216359), Rafa Laboratories, Ltd., effective February 18, 2026 (SPL set d7362b4d-68a3-99a0-e053-2995a90a4f60), via openFDA
Source: FDA drug label (Midazolam In Sodium Chloride, NDA211844), WG Critical Care, LLC., effective July 31, 2025 (SPL set f051776f-94c5-4e34-80ed-f45b9c36881e), via openFDA
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cimetidine | Midazolam | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.236 per tablet 300 mg tablet | $0.233 per mL 2 mg/2 mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once